11:30 AM - 1:00 PM
The Racquet Club of Philadelphia
Can-Fite BioPharma Ltd. (NYSE American: CANF) is an advanced clinical stage drug development company with a platform technology that addresses multi-billion dollar markets in the treatment of cancer, liver disease, inflammatory diseases, and sexual dysfunction. Can-Fite’s drugs have an excellent safety profile with experience in over 1,000 patients. The Company’s lead drug candidate, Piclidenoson (CF101) is expected to enter Phase III trials in two indications, rheumatoid arthritis and psoriasis. Can-Fite’s liver drug Namodenoson (CF102) completed patient enrollment in a Phase II trial for patients with advanced liver cancer and is slated to enter Phase II for the treatment of NAFLD/NASH. Piclidenoson and Namodenoson have been out-licensed in select territories with $11.5 million received to date. CF602, the Company’s third drug candidate, has shown efficacy in the treatment of erectile dysfunction in preclinical studies. Can-Fite’s intellectual property portfolio consists of 120 patents issued and pending.